Avexa Limited Collaborates With TargetDrug on HCV Program

MELBOURNE, Australia--(BUSINESS WIRE)--Australian biotechnology company Avexa Ltd (ASX:AVX) announced today that it will collaborate with TargetDrug on its Hepatitis C virus (HCV) program. The focus will be on the development of novel lead inhibitors of HCV replication. The Company also provided an update on the progress of its Apricitabine (ATC) Phase III trials.

Back to news